OXYGENTAPH
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
- 
                
Share Price
 - 
                
Financials
 - 
                
Revenue mix
 - 
                
Shareholdings
 - 
                
Peers
 - 
                
Forensics
 
- 5D
 - 1M
 - 6M
 - YTD
 - 1Y
 - 5Y
 - MAX
 
This data is currently unavailable for this company.
- 
            
Summary
 - 
            
Profit & Loss
 - 
            
Balance sheet
 - 
            
Cashflow
 
This data is currently unavailable for this company.
| (In Cr.) | 
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
| 
                        
                         This data is currently unavailable for this company.  | 
                    
| (In %) | 
|---|
| (In Cr.) | 
|---|
| Financial Year (In Cr.) | 
|---|
- 
        
Product wise
 - 
        
Location wise
 
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
- 
                
News
 - 
                
Corporate Actions
 
Oxygenta Pharmaceutical Says Vankineni Sai Sudhakar Resigns As MD, CFO
Aug 19 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
VANKINENI SAI SUDHAKAR RESIGNS AS MD, CFO
Source text: ID:nBSE4TFvYj
Further company coverage: OXPH.BO
(([email protected];;))
Aug 19 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
VANKINENI SAI SUDHAKAR RESIGNS AS MD, CFO
Source text: ID:nBSE4TFvYj
Further company coverage: OXPH.BO
(([email protected];;))
Oxygenta Pharmaceutical To Consider Raising Of Funds
April 3 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE5KyRgf
Further company coverage: OXPH.BO
(([email protected];))
April 3 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
TO CONSIDER RAISING OF FUNDS
Source text for Eikon: ID:nBSE5KyRgf
Further company coverage: OXPH.BO
(([email protected];))
Oxygenta Pharmaceutical Reappoints Sai Sudhakar Vankineni As MD
Sept 4 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
REAPPOINTS SAI SUDHAKAR VANKINENI AS MD
Source text for Eikon: ID:nBSE9Y1b5c
Further company coverage: OXPH.BO
(([email protected];))
Sept 4 (Reuters) - Oxygenta Pharmaceutical Ltd OXPH.BO:
REAPPOINTS SAI SUDHAKAR VANKINENI AS MD
Source text for Eikon: ID:nBSE9Y1b5c
Further company coverage: OXPH.BO
(([email protected];))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- 
                
Business
 - 
                
Financials
 - 
                
Share Price
 - 
                
Shareholdings
 
What does Oxygenta Pharma do?
SS Organics Ltd is a pharmaceutical company that focuses on producing and marketing bulk drugs and intermediates, specializing in new-generation medications such as quinolones, antiasthmatics, antiulcerants, and anti-inflammatories.
Who are the competitors of Oxygenta Pharma?
Oxygenta Pharma major competitors are Syschem (India), BDH Inds, Ambalal Sarabhai Ent, Natural Capsules, Sanjivani Paranteral, Aayush Wellness, Aarey Drugs & Pharma. Market Cap of Oxygenta Pharma is ₹236 Crs. While the median market cap of its peers are ₹240 Crs.
Is Oxygenta Pharma financially stable compared to its competitors?
Oxygenta Pharma seems to be less financially stable compared to its competitors. Altman Z score of Oxygenta Pharma is 0.3 and is ranked 8 out of its 8 competitors.
Does Oxygenta Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Oxygenta Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Oxygenta Pharma allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory
How strong is Oxygenta Pharma balance sheet?
Oxygenta Pharma balance sheet is weak and might have solvency issues
Is the profitablity of Oxygenta Pharma improving?
No, profit is decreasing. The profit of Oxygenta Pharma is -₹15.04 Crs for TTM, -₹9.68 Crs for Mar 2025 and -₹3.48 Crs for Mar 2024.
Is the debt of Oxygenta Pharma increasing or decreasing?
Yes, The net debt of Oxygenta Pharma is increasing. Latest net debt of Oxygenta Pharma is ₹61.99 Crs as of Mar-25. This is greater than Mar-24 when it was ₹57.03 Crs.
Is Oxygenta Pharma stock expensive?
There is insufficient historical data to gauge this. Latest PE of Oxygenta Pharma is 0
Has the share price of Oxygenta Pharma grown faster than its competition?
Oxygenta Pharma has given better returns compared to its competitors. Oxygenta Pharma has grown at ~21.65% over the last 9yrs while peers have grown at a median rate of 20.93%
Is the promoter bullish about Oxygenta Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Oxygenta Pharma is 57.95% and last quarter promoter holding is 57.95%.
Are mutual funds buying/selling Oxygenta Pharma?
The mutual fund holding of Oxygenta Pharma is stable. The current mutual fund holding in Oxygenta Pharma is 0.03% while previous quarter holding is 0.03%.
